OVERPRODUCTION OR APOB IS FREQUENT IN FCHL, A GENETICALLY HETEROGENEOUS DISORDER. IN MOST FCHL CASES, HMGCOA REDUCTASE INHIBITORS DECREASE APOB LEVELS BE DECREASING APOB PRODUCTION. WE REPORT AN UNUSUAL KINDRED WITH LOW VLDL- AND LDL-APOB FCR AS THE MAIN KINETIC DEFECTS. FIVE MEMBERS OF THE KINDRED, 3 WITH MIXED HYPERLIPIDEMIA, 1 HYPERCHOLESTEROLEMIA AND 1 HYPERTRIGLYCERIDEMIA, PARTICIPATED IN A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED CROSSOVER STUDY. SIX WEEK TREATMENT PERIODS WERE SEPARATED BY 2 WEEK WASHOUTS. PRAVASTATIN (20MG/DAY) LOWERED PLASMA CHOLESTEROL (212117 VS 268126 MG/DL, P<0.05), LDL CHOLESTEROL (14218.7 VS 185131 MG/DL, P<0.05), AND APOB (124112 VS 169115.5 MG/DL, P<0.05), BUT DID NOT CHANGE HDL CHOLESTEROL OR LP(A). METABOLIC PARAMETERS OF APOB WERE DETERMINED WITH THE ENDOGENOUS LABEL C13-LEUCINE AND A MULTICOMPARTMENTAL MODEL. DURING PLACEBO TREATMENT VLDL APOB FCRS WERE 3.611.1 VS 9.212.9 POOLS/DAY FOR 9 NORMOLIPIDEMIC CONTROLS. LDL APOB FCRS WERE 0.1910.05 VS 0.4110.13. VLDL APOB PRODUCTION WAS NORMAL. MOST LDL WERE IN THE DENSITY RANGE 1.036 < D < 1.063 G/ML AND HAD FCRS OF 0.2210.08. FCRS OF LIGHT LDL WERE 0.8210.21. PRAVASTATIN INCREASED LDL APOB FCRS IN ALL CASES FROM 0.1910.05 TO 0.3410.04. BOTH LDL SUBCLASSES WERE SIMILARLY AFFECTED. WE CONCLUDE THAT FCHL IS KINETICALLY HETEROGENEOUS AND THAT IN THIS KINDRED PRAVASTATIN LOWERED LDL LEVELS BY INCREASING THE LDL FCR.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Biotechnology Resource Grants (P41)
Project #
5P41RR002176-10
Application #
5223836
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
1996
Total Cost
Indirect Cost
Wolfe, B M; Barrett, P H; Laurier, L et al. (2000) Effects of continuous conjugated estrogen and micronized progesterone therapy upon lipoprotein metabolism in postmenopausal women. J Lipid Res 41:368-75
Vicini, P; Zachwieja, J J; Yarasheski, K E et al. (1999) Glucose production during an IVGTT by deconvolution: validation with the tracer-to-tracee clamp technique. Am J Physiol 276:E285-94
Parhofer, K G; Barrett, P H; Schwandt, P (1999) Low density lipoprotein apolipoprotein B metabolism: comparison of two methods to establish kinetic parameters. Atherosclerosis 144:159-66
Vicini, P; Caumo, A; Cobelli, C (1999) Glucose effectiveness and insulin sensitivity from the minimal models: consequences of undermodeling assessed by Monte Carlo simulation. IEEE Trans Biomed Eng 46:130-7
Burnett, J R; Wilcox, L J; Telford, D E et al. (1999) The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs. Endocrinology 140:5293-302
Vicini, P; Cobelli, C (1999) A priori identifiability of distributed models of blood-tissue exchange. Ann Biomed Eng 27:200-7
Cobelli, C; Caumo, A; Omenetto, M (1999) Minimal model SG overestimation and SI underestimation: improved accuracy by a Bayesian two-compartment model. Am J Physiol 277:E481-8
Bertoldo, A; Vicini, P; Sambuceti, G et al. (1998) Evaluation of compartmental and spectral analysis models of [18F]FDG kinetics for heart and brain studies with PET. IEEE Trans Biomed Eng 45:1429-48
Barrett, P H; Bell, B M; Cobelli, C et al. (1998) SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. Metabolism 47:484-92
Cobelli, C; Caumo, A (1998) Using what is accessible to measure that which is not: necessity of model of system. Metabolism 47:1009-35

Showing the most recent 10 out of 69 publications